{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:34:42Z","timestamp":1715596482275},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"DOI":"10.1093\/ndt\/gfk086","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T18:33:02Z","timestamp":1138818782000},"page":"854-858","source":"Crossref","is-referenced-by-count":20,"title":["Is it time for spironolactone therapy in dialysis patients?"],"prefix":"10.1093","volume":"21","author":[{"given":"Adrian","family":"Covic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gusbeth-Tatomir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J. A.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,1,31]]},"reference":[{"key":"key\n\t\t\t\t20171011045606_BIB1","doi-asserted-by":"crossref","unstructured":"Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci2002; 970: 89\u2013100","DOI":"10.1111\/j.1749-6632.2002.tb04415.x"},{"key":"key\n\t\t\t\t20171011045606_BIB2","doi-asserted-by":"crossref","unstructured":"Aldigier JC, Kanjanbuch T, Ma LJ et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol2005; 16: 3306\u20133314","DOI":"10.1681\/ASN.2004090804"},{"key":"key\n\t\t\t\t20171011045606_BIB3","doi-asserted-by":"crossref","unstructured":"Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med2001; 345: 925\u2013926","DOI":"10.1056\/NEJM200109203451215"},{"key":"key\n\t\t\t\t20171011045606_BIB4","doi-asserted-by":"crossref","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension2003; 41: 64\u201368","DOI":"10.1161\/01.HYP.0000044937.95080.E9"},{"key":"key\n\t\t\t\t20171011045606_BIB5","doi-asserted-by":"crossref","unstructured":"Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis2005; 46: 45\u201351","DOI":"10.1053\/j.ajkd.2005.03.007"},{"key":"key\n\t\t\t\t20171011045606_BIB6","doi-asserted-by":"crossref","unstructured":"Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol2004; 16: 489\u2013495","DOI":"10.1681\/ASN.2004030203"},{"key":"key\n\t\t\t\t20171011045606_BIB7","doi-asserted-by":"crossref","unstructured":"Parfrey PS. The clinical epidemiology of cardiovascular disease in chronic kidney disease. Semin Dial2003; 16: 83\u201384","DOI":"10.1046\/j.1525-139X.2003.16022.x"},{"key":"key\n\t\t\t\t20171011045606_BIB8","doi-asserted-by":"crossref","unstructured":"Culleton BF, Hemmelgarn B. Inadequate treatment of cardiovascular disease and cardiovascular disease risk factors in dialysis patients: a commentary. Semin Dial2004; 17: 342\u2013345","DOI":"10.1111\/j.0894-0959.2004.17360.x"},{"key":"key\n\t\t\t\t20171011045606_BIB9","doi-asserted-by":"crossref","unstructured":"Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med2001; 110: 438\u2013441","DOI":"10.1016\/S0002-9343(01)00642-8"},{"key":"key\n\t\t\t\t20171011045606_BIB10","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med1999; 341: 709\u2013717","DOI":"10.1056\/NEJM199909023411001"},{"key":"key\n\t\t\t\t20171011045606_BIB11","doi-asserted-by":"crossref","unstructured":"Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalaemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med2004; 351: 543\u2013551","DOI":"10.1056\/NEJMoa040135"},{"key":"key\n\t\t\t\t20171011045606_BIB12","doi-asserted-by":"crossref","unstructured":"MacDonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart2004; 90: 765\u2013770","DOI":"10.1136\/hrt.2003.017368"},{"key":"key\n\t\t\t\t20171011045606_BIB13","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med2003; 348: 1309\u20131321","DOI":"10.1056\/NEJMoa030207"},{"key":"key\n\t\t\t\t20171011045606_BIB14","doi-asserted-by":"crossref","unstructured":"Ravis WR, Reid S, Sica DA et al. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol2005; 45: 810\u2013821","DOI":"10.1177\/0091270005275894"},{"key":"key\n\t\t\t\t20171011045606_BIB15","doi-asserted-by":"crossref","unstructured":"Aoki J, Ikari Y, Nakajima H et al. Clinical and pathologic characteristics of dilated cardiomyopathy in haemodialysis patients. Kidney Int2005; 67: 333\u2013340","DOI":"10.1111\/j.1523-1755.2005.00086.x"},{"key":"key\n\t\t\t\t20171011045606_BIB16","doi-asserted-by":"crossref","unstructured":"Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res2004; 61: 663\u2013670","DOI":"10.1016\/j.cardiores.2003.11.037"},{"key":"key\n\t\t\t\t20171011045606_BIB17","doi-asserted-by":"crossref","unstructured":"Weber KT. Aldosterone in congestive heart failure. N Engl J Med2001; 345: 1689\u20131697","DOI":"10.1056\/NEJMra000050"},{"key":"key\n\t\t\t\t20171011045606_BIB18","doi-asserted-by":"crossref","unstructured":"Lacolley P, Labat C, Pujol A et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation2002; 106: 2848\u20132853","DOI":"10.1161\/01.CIR.0000039328.33137.6C"},{"key":"key\n\t\t\t\t20171011045606_BIB19","doi-asserted-by":"crossref","unstructured":"Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Arterial stiffness in renal patients: an update. Am J Kidney Dis2005; 45: 965\u2013977","DOI":"10.1053\/j.ajkd.2005.02.026"},{"key":"key\n\t\t\t\t20171011045606_BIB20","doi-asserted-by":"crossref","unstructured":"London GM, Marchais SJ, Gu\u00e9rin AP et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens2005; 14: 525\u2013531","DOI":"10.1097\/01.mnh.0000168336.67499.c0"},{"key":"key\n\t\t\t\t20171011045606_BIB21","doi-asserted-by":"crossref","unstructured":"Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with haemodialysis. Am J Hypertens1999; 12: 867\u2013873","DOI":"10.1016\/S0895-7061(99)00066-7"},{"key":"key\n\t\t\t\t20171011045606_BIB22","doi-asserted-by":"crossref","unstructured":"Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol1998; 9: 1535\u20131543","DOI":"10.1681\/ASN.V981535"},{"key":"key\n\t\t\t\t20171011045606_BIB23","unstructured":"Hayes CP, McLeod ME, Robinson RR. An extravenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians1967; 80: 207\u2013216"},{"key":"key\n\t\t\t\t20171011045606_BIB24","doi-asserted-by":"crossref","unstructured":"Colussi G, Dossi F. Aldosterone and potassium balance in dialysis patients. Nephrol Dial Transplant2004; 19: 1938\u20131939","DOI":"10.1093\/ndt\/gfh264"},{"key":"key\n\t\t\t\t20171011045606_BIB25","doi-asserted-by":"crossref","unstructured":"Iseki K, Uehara H, Nishime K et al. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis1996; 28: 541\u2013548","DOI":"10.1016\/S0272-6386(96)90465-5"},{"key":"key\n\t\t\t\t20171011045606_BIB26","doi-asserted-by":"crossref","unstructured":"Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int2001; 60: 350\u2013357","DOI":"10.1046\/j.1523-1755.2001.00806.x"},{"key":"key\n\t\t\t\t20171011045606_BIB27","unstructured":"Papadimitriou M, Vyzantiadis A, Milionis A et al. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Syst1979; 1: 197\u2013205"},{"key":"key\n\t\t\t\t20171011045606_BIB28","doi-asserted-by":"crossref","unstructured":"Hussain S, Dreyfus DE, Marcus RJ et al. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant2003; 18: 2364\u20132368","DOI":"10.1093\/ndt\/gfg413"},{"key":"key\n\t\t\t\t20171011045606_BIB29","doi-asserted-by":"crossref","unstructured":"Saudan P, Mach F, Perneger T et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant2003; 18: 2359\u20132363","DOI":"10.1093\/ndt\/gfg388"},{"key":"key\n\t\t\t\t20171011045606_BIB30","doi-asserted-by":"crossref","unstructured":"Gross E, Rothstein M, Dombek S et al. Effect of spironolactone on blood pressure and the renin\u2013angiotensin\u2013aldosterone system in oligo-anuric haemodialysis patients. Am J Kidney Dis2005; 46: 94\u2013101","DOI":"10.1053\/j.ajkd.2005.03.005"},{"key":"key\n\t\t\t\t20171011045606_BIB31","doi-asserted-by":"crossref","unstructured":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol1996; 78: 902\u2013907","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"key\n\t\t\t\t20171011045606_BIB32","doi-asserted-by":"crossref","unstructured":"Hausmann MJ, Liel-Cohen N. Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant2002; 17: 2035\u20132036","DOI":"10.1093\/ndt\/17.11.2035"},{"key":"key\n\t\t\t\t20171011045606_BIB33","doi-asserted-by":"crossref","unstructured":"Azar R, Hogede L, Carru V. Aldactone therapy in a peritoneal dialysis patient. Nephrol Dial Transplant2003; 18: 1232","DOI":"10.1093\/ndt\/gfg088"},{"key":"key\n\t\t\t\t20171011045606_BIB34","doi-asserted-by":"crossref","unstructured":"Khan AN, Bernardini J, Johnston JR, Piraino B. Hypokalaemia in peritoneal dialysis patients. Perit Dial Int1996; 16: 652","DOI":"10.1177\/089686089601600628"},{"key":"key\n\t\t\t\t20171011045606_BIB35","doi-asserted-by":"crossref","unstructured":"Phakdeekitcharoen B, Leelasa-Nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis2004; 44: 738\u2013746","DOI":"10.1016\/S0272-6386(04)00954-0"},{"key":"key\n\t\t\t\t20171011045606_BIB36","doi-asserted-by":"crossref","unstructured":"Fenwick S, Bell GM. Aldactone therapy in a peritoneal dialysis patient. Nephrol Dial Transplant2003; 18: 1232","DOI":"10.1093\/ndt\/gfg098"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/4\/854\/12881700\/gfk086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T11:40:16Z","timestamp":1627040416000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/4\/854\/1932617\/Is-it-time-for-spironolactone-therapy-in-dialysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,31]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,1,31]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfk086","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,4]]},"published":{"date-parts":[[2006,1,31]]}}}